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Transcatheter aortic valve replacement (TAVR) is an established alternative to surgical
valve replacement for patients with severe aortic stenosis (AS) and increased surgical risk.
On the basis of the favorable outcomes of recent randomized clinical trials conducted
in intermediate and low risk populations, TAVR is expected in the near future to be
offered to patients not only at lower surgical risk, but also with longer life expectancy.
In this particular subset, the long-term durability of the bioprosthetic valve is of critical
importance. The European Association of Percutaneous Cardiovascular Interventions
(EAPCI), the European Society of Cardiology (ESC), and the European Association for
Cardio-Thoracic Surgery (EACTS) recently introduced standardized criteria to define
structural valve deterioration (SVD) and valve failure of transcatheter and surgical aortic
bioprosthesis—this with the aim to generate uniformity in data reporting in future studies
assessing long-term durability of aortic bioprosthesis. On this background, the aim
of this article is to review the definition, incidence and predictors of transcatheter
bioprosthetic valve dysfunction, including structural and non-structural valve deterioration
(SVD/NSVD), valve thrombosis, and endocarditis.
Keywords: aortic valve replacement, transcatheter, valve dysfunction, valve deterioration, thrombosis,
endocarditis
INTRODUCTION
The clinical impact of transcatheter aortic valve replacement (TAVR) has been important by
addressing the need for a therapeutic treatment in selected inoperable patients with symptomatic
severe aortic stenosis (AS), but also as an alternative to surgical aortic valve replacement (SAVR) in
patients at increased surgical risk. Based on large randomized controlled trials (RCTs) comparing
TAVR to SAVR in patients with severe AS and intermediate or lower surgical risk (1–3), both
the guidelines from the European Society of Cardiology (ESC) and the European Association for
Cardio-Thoracic Surgery (EACTS) as well as the guidelines from the American Heart Association
(AHA) and American College of Cardiology (ACC) were updated in 2017, upgrading the indication
for TAVR to patients with symptomatic severe AS and intermediate surgical risk (4–6). Within
the past decade, national registries have reported a steady growth in the annual number of TAVR
procedures performed (7–10) and a decrease in the mean age of patients undergoing TAVR (8). The
anticipation of treating AS patients with a longer life expectancy by means of TAVR has intensified
the concerns about the durability of transcatheter heart valves (THVs).
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Recently, two randomized clinical trials including patients
with low surgical risk were presented. The Evolut Low Risk
trial reported that TAVR with a self-expanding THV was non-
inferior to SAVR with regard to all-cause mortality or disabling
stroke within 2 years of the procedure (11). The PARTNER 3
trial reported that TAVR with a balloon-expandable THV was
superior to SAVR with regard to the 1-year risk of all-cause
mortality, stroke, or re-hospitalization (12). Themean age in both
trials was 74 years of age. Considering these results, it is likely
that the indication for TAVR will not only expand to patients
with lower surgical risk but also to patients at younger age than
currently treated by TAVR. Consequently, with the increased
life expectancy of these patients, it is more likely that they will
outlive their implanted THV. There are only few data regarding
long-term THV durability. Assessment of valve function in the
early randomized TAVR trials and registries have consistently
shown preserved valve function up to 5 years after TAVR (13, 14).
However, it is well-documented that valve degeneration with
surgical aortic bioprostheses is usually not seen until 5–10 years
post-procedure (15).
The aim of this article is to review the definition, incidence and
predictors of transcatheter bioprosthetic aortic valve dysfunction,
including structural and non-structural valve deterioration
(SVD/NSVD), valve thrombosis, and endocarditis (Figure 1).
STRUCTURAL VALVE DETERIORATION
The durability of surgical aortic bioprosthesis has been more
extensively described compared with THVs, mainly due to SAVR
being performed for a longer time. However, previous studies
FIGURE 1 | Causes of bioprosthetic valve dysfunction. Figure used with permission from Oxford University Press (16).
reporting on surgical heart valves have tended to use the need
for re-intervention as a clinical endpoint for SVD (17–20)—
resulting in a risk of under-estimating the incidence of SVD as
some patients might have become too frail over time to undergo
redo-SAVR, even though the surgical aortic bioprosthesis might
have been deteriorated (20, 21). Some echocardiographic criteria
for defining SVD have been applied in individual studies (22);
however, the lack of a consensus definition for SVD limits the
possibility for comparison across studies.
Efforts have been made to standardize the definition of
SVD for both transcatheter and surgical bioprostheses. Building
on existing definitions for SVD, a consensus statement from
the European Association of Percutaneous Cardiovascular
Interventions (EAPCI)—endorsed by the ESC and the EACTS—
was published in 2017 (16). SVD was classified into either
morphological or moderate and severe hemodynamic SVD based
on the severity of THV stenosis and/or regurgitation (16). The
VIVID (Valve in Valve International Data) group published a
similar but more staged classification for SVD, Table 1 (22).
SVD is commonly defined as an intrinsic permanent change of
the bioprosthesis due to leaflet calcification, thickening, pannus
formation, tear, or disruption. The resulting deterioration leads
to stenosis and/or intra-prosthetic regurgitation (16, 21–23).
A study including 2,659 patients undergoing SAVR reported
that the time to deterioration of surgical bioprostheses was
similar regardless of stenotic and/or regurgitation etiology (21).
Further, younger age was found as a significant risk factor for
early SVD (17, 21). The increased risk of SVD in younger patients
is thought to be mediated by a higher metabolic rate and a
stronger immunological response to the implanted bioprosthetic
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TABLE 1 | Proposed definitions of structural valve deterioration (SVD).
Valve Academic Research Consortium (VARC)-2 (2013)
Structural Valve Deterioration (SVD)
• Valve related dysfunction (any of the following):
◦ Mean gradient ≥ 20 mmHg
◦ Effective orifice area (EOA) ≤ 0.9–1.1 cm2
◦ Doppler Velocity Index (DVI) < 0.35 m/s
◦ Moderate or severe prosthetic valve regurgitation
• Requiring repeat procedure aortic valve replacement
European Association of Percutaneous Cardiovascular Interventions
(EAPCI) endorsed by ESC and EACTS (2017)
Morphological SVD (any of the following):
• Leaflet integrity, structure, or function abnormality (i.e., flail, pathological
thickening, calcification, impaired mobility causing central regurgitation, or
valvular stenosis)
• Strut/frame abnormality (i.e., fracture)
Moderate hemodynamic SVD (any of the following):
• Mean gradient ≥ 20 and <40 mmHg
• Mean gradient ≥ 10 and <20 mmHg change from baseline
• Moderate intra-prosthetic aortic regurgitation, new or worsening (>1/4)
from baseline
Severe hemodynamic SVD (any of the following):
• Mean gradient ≥ 40 mmHg
• Mean gradient ≥ 20 mmHg change from baseline
• Severe intra-prosthetic aortic regurgitation, new or worsening (>2/4)
from baseline
Valve-in-valve international data registry (VIVID) investigators (2018)
SVD stage 0
• No significant change from immediate post-implantation
SVD stage 1
• Morphological leaflet abnormality without significant hemodynamic changes
SVD stage 2S
• Moderate stenosis (mean gradient ≥ 20 and <40 mmHg)
• ≥10 mmHg increase from baseline status concomitant with increase in EOA
and DVI
• Thrombotic leaflet thickening excluded
SVD stage 2R
• Moderate regurgitation
• Exclude that paravalvular regurgitation is main component
SVD stage 2RS
• Stage 2S and 2R
SVD stage 3D (any of the following)
• Severe stenosis (mean gradient ≥ 40 mmHg)
• Severe regurgitation
heart valve (19). Other factors that have been found to increase
the risk of SVD of aortic bioprostheses are patient-prosthesis
mismatch (PPM), dialysis, hyperparathyroidism, and diabetes
(17, 19, 24, 25).
In addition, it has been hypothesized that several risk factors
of SVD might specifically apply to THVs. The need to crimp
the THV into a delivery catheter may theoretically damage the
bioprosthetic leaflet tissue, thereby impairing THV durability
(26). During TAVR, it is not aimed to align the commissures of
the THV to those of the native aortic valve, and commissural
misalignment might increase the stress on the leaflets and
has been reported to increase the risk of mild intra-prosthetic
regurgitation (27). Lastly, there is no data on the impact of
elliptical THV geometry due to calcified native aortic annulus or
incomplete expansion of the THV due to oversizing.
So far, there is only limited data available on long-term
durability of THVs, as those patients treated by TAVR in the early
years of the procedure were typically elderly and frail patients.
Consequently, the expected and observed medium-term survival
rate of these initially treated TAVR-patients is relatively low,
Table 2. As abovementioned, age also likely plays a crucial inverse
role in the rate of SVD. This further limits the possibility to
predict the rate of SVD based on the currently treated patients
whom are likely older than the future TAVR patients.
Only few data exist on controlled comparison of SVD between
surgical and transcatheter aortic bioprosthesis. In general, these
studies find the medium-long term risk of severe SVD to be low,
ranging between 0 and 2.5% in studies with 4–8 years of follow-
up (32, 35, 37–40). In the PARTNER-1 trial, there was no SVD
reported at 5 years—although only 15 patients remained alive
(13). In the CoreValve High Risk Pivotal trial, severe SVD was
noted in 1.7% and 0.8% of patients at 5 years after SAVR and
TAVR (p = 0.32), respectively (32). The standardized criteria
of SVD from EAPCI/ESC/EACTS were recently also applied to
the NOTION trial—a RCT randomizing AS patients at lower
surgical risk to SAVR or TAVR. This patient population had
a lower mortality rate as compared to contemporary RCTs in
high-to-intermediate risk patients. The risk of SVD through 6
years for surgical and transcatheter bioprostheses was 24.0 and
4.8% (p < 0.0001), respectively (37). This difference was mainly
driven by moderate SVD in the SAVR group and severe SVD
was observed in 3.0% vs. 0.7% in the SAVR vs. TAVR group,
respectively (p= 0.21) (37).
NON-STRUCTURAL VALVE
DETERIORATION
Non-SVD is a bioprosthetic abnormality due to extrinsic
factors such as PPM, paravalvular regurgitation (PVR), device
malpositioning, or abnormal frame expansion. The presence of
non-SVD is not an intrinsic deterioration of the bioprosthesis
or leaflets—however, it might mediate early development of SVD
(16, 22, 41).
Following SAVR, the prevalence of moderate PPM ranges
from 20 to 70% and that of severe PPM from 2 to 20% (42,
43). TAVI is associated with a lower prevalence of (especially
severe) PPM as compared to SAVR (44, 45). Among THVs,
self-expanding valves with supra-annular design are generally
associated with a lower prevalence of PPM as compared
with balloon-expandable valves. Patients with PPM have worse
symptoms and exercise capacity, higher rate of heart failure re-
hospitalization, and increased mortality after SAVR as compared
with patients with no PPM (42, 46). PPM is also associated with
quicker structural degeneration of surgical aortic bioprostheses
(24, 47). Consequently, TAVR could be the preferred choice of
treatment for patients with a small annulus (valve size < 23mm)
in whom PPM can be anticipated in case of SAVR.
On the contrary, THVs more frequently have PVR. However,
with the newer generation THVs—with often an additional
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TABLE 2 | Incidence of structural valve deterioration of transcatheter heart valves.
References
(definition used)
Valve type—number 5-year survival Median F/U (months) Structural valve deterioration
Aldalati et al. (28)
(EAPCI/ESC/EACTS)
Sapien: 52
Sapien XT: 156
Sapien 3: 51
Lotus: 6
Jena valve: 2
Others: 2
45% 33 Moderate/severe: 33%
(6.5 year estimate)
Gerckens et al. (29)
(VARC-2)
CoreValve: 996 49% 36 Moderate/severe: 2.6%
Eltchaninoff et al. (30)
(EAPCI/ESC/EACTS)
Cribier: 79
Sapien: 83
Sapien XT: 216
32% 36 Moderate/severe: 3.2%
(8 year estimate)
Barbanti et al. (31)
(N/A)
CoreValve: 353 45% 47 Moderate/severe: 3.7%
Gleason et al. (32)
(EAPCI/ESC/EACTS)
CoreValve: 391 N/A 50 Severe: 0.8%
Toggweiler et al. (33)
(VARC-1)
Cribier: 49
Sapien: 39
35% 60 Moderate: 3.4%
Mack et al. (34)
(N/A)
Sapien: 348 32% 60 Moderate/severe central regurgitation:
0.7%
Blackman et al. (35)
(EAPCI/ESC/EACTS)
Sapien: 45
Sapien XT: 35
CoreValve: 149
Portico: 4
N/A 69 Moderate: 8.7%
Severe: 0.4%
Panico et al. (36)
(EAPCI/ESC/EACTS)
CoreValve: 278 45% 70 Moderate/severe: 3.6%
Søndergaard et al. (37)
(EAPCI/ESC/EACTS)
CoreValve: 139 72% 72 Moderate: 3.6%
Severe: 0.7%
Holy et al. (38)
(EAPCI/ESC/EACTS)
CoreValve: 152 50% 75 Severe: 0%
Didier et al. (39)
(EAPCI/ESC/EACTS)
Self-exp.: 1,413
Balloon-exp.: 2,774
39% N/A Moderate: 10.8%
Severe: 2.5%
(5 years estimate)
Barbanti et al. (40)
(EAPCI/ESC/EACTS)
CoreValve: 238
Sapien XT: 48
55% N/A Moderate: 5.9%
Severe: 2.4%
(8 years estimate)
sealing skirt around the valve prosthesis stent frame—these PVR
rates have come down to a range of 1–3% for moderate PVR
and 29–36% for mild PVR in the latest low-risk TAVR trials
(11, 12). The impact of mild PVR on left ventricular function,
symptoms, and long-term mortality in lower risk patients with
longer life expectancy is still unknown—however, data from
the PARTNER-1 trial have suggested decrease survival in this
subset (13).
Finally, whether abnormal stent frame expansion—as
sometimes observed in case of THV in heavily calcified or
bicuspid valves—has a negative impact on valve durability is
unknown. In an ex-vivo bench study by Sathananthan et al., it
was shown that excessive THV overexpansion may be associated
with impaired hydrodynamic function, acute leaflet failure, and
reduced durability. Smaller valves may be at greater risk with
overexpansion than larger valves. Similar, THV undersizing can
cause leaflet pin wheeling and reduced durability (48).
In conclusion, future TAVR studies including patients with
longer life expectancy and bicuspid valve anatomy are needed to
answer these remaining open questions.
VALVE THROMBOSIS
Clinical valve thrombosis after TAVR typically presents with an
increase of transvalvular gradient and symptoms of heart failure
caused by obstructing thrombus in the THV. On the other hand,
subclinical leaflet thrombosis is an incidental finding on 4DCT
or TEE imaging, which does not cause symptoms or elevated
transvalvular pressure gradients outside the normal range.
In a study by Bourguignon et al. (21) with long-term follow-up
data on 2,659 Carpentier-Edwards Perimount valves in the aortic
position, no single case of clinical valve thrombosis was reported
with a median follow-up of 6.7 years (21). In accordance, there
was no clinical valve thrombosis observed in the NOTION lower-
risk trial—neither in the TAVR nor in the SAVR population—
with a follow-up of up to 6 years (37). In two retrospective
analyses, the prevalence of clinical valve thrombosis was reported
to be 0.6 and 2.8% after TAVR (49, 50), whereas the prevalence of
subclinical leaflet thrombosis has been reported to be as high as
15–35% in studies assessing this phenomenon by means of TEE
and/or 4DCT cardiac imaging (51–53).
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FIGURE 2 | Clinical valve thrombosis and subclinical leaflet thrombosis. (A,B) Transesophageal echocardiography (TEE) showing valve thrombosis and turbulent color
flow over the transcatheter aortic bioprosthesis in a patient presenting with an elevated mean transvalvular gradient at transthoracic echocardiography (TTE, 37
mmHg) and dyspnea NYHA class 3–4, and this few years after TAVR. (C) The thrombotic mass at the aortic side of the prosthetic leaflets was confirmed by
intracardiac echocardiography (ICE). (D,E) Incidental finding of hypoattenuating leaflet thickening (HALT) at the base of the transcatheter heart valve leaflets, with
hypoattenuation affecting motion (HAM) visible in systole in the volume-rendered 4D computed tomography (4DCT) images; (F) this reduced leaflet motion of two
leaflets was confirmed by TEE. (G–I) Resolution of the leaflet thickening and reduced leaflet motion following 3 months of anticoagulation treatment, as shown by
4DCT and TEE imaging.
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Although usually an incidental finding, there has been a
concern that subclinical leaflet thrombosis may progress into
clinical valve thrombosis, cause stroke or other thromboembolic
events, and/or impair the durability of the THV.
Reports on a potential association between subclinical leaflet
thrombosis and stroke/transient ischemic attack (TIA) have
raised concerns. In the SAVORY and RESOLVE registries,
subclinical leaflet thrombosis with reduced leaflet motion was
associated with increased incidence of TIA (53). In contrast, a
prospective trial—including 4DCT or echocardiography in 434
patients that underwent TAVR—did not show any increased
stroke risk at 3 years of follow-up in those patients diagnosed
with (possible) subclinical leaflet thrombosis (54). One meta-
analysis, although involving a limited number of retrospective
studies, also reported an overall odds ratio of 3.38 (95% CI:
1.78–6.41, P < 0.001) for cerebrovascular events in case of
hypo-attenuation affecting motion (HAM) as compared with
hypo-attenuation affecting leaflet thickening (HALT) only—
thereby suggesting an impact of “thrombus burden” on the
risk for neurological events (55). However, it should be kept
in mind that all these reports are based on retrospective data
and often there is a very long temporal separation between the
neurological event and the cardiac imaging showing subclinical
leaflet thrombosis.
Anticoagulation seems to be preventive for development of
both clinical valve thrombosis and subclinical leaflet thrombosis,
whereas single or dual APT does not have this protective effect.
In accordance, treatment with anticoagulation seems to have—
at least temporarily—beneficial effects on restoration of leaflet
motion and transvalvular gradients in case of THV thrombosis
(50, 51, 56) (Figure 2). In addition, Del Trigo et al. reported that
absence of anticoagulant therapy at hospital discharge was an
independent predictor of hemodynamic valve deterioration after
TAVR (57).
Finally, although subclinical leaflet thrombosis seems to
be more common after TAVR as compared with SAVR,
medium-term durability of THVs has been reported to
be non-inferior to surgical aortic bioprosthesis in several
large randomized trials (32, 34). Whether, subclinical leaflet
thrombosis may be a precursor and/or predictor of valve
dysfunction on the longer-term is unknown. Long-term follow-
up data on THV and surgical bioprosthesis—including leaflet-
imaging studies—will be needed in order to give an answer to
this question.
ENDOCARDITIS
Another important reversible mechanism of non-SVD is the
development of valve failure due to infective endocarditis. In
the NOTION lower-risk trial, the risk of infective endocarditis
was similar after SAVR (5.9%) as compared to TAVR (5.8%)
after 6 years of follow-up (37). In accordance, Butt et al.
(58) recently reported long-term follow-up data from a Danish
nationwide observational study comprising 2,632 TAVR patients
and 3,777 matched SAVR patients. During a mean follow-
up of 3.6 years, 115 patients (4.4%) with TAVR and 186
patients (4.9%) with SAVR were admitted with infective
endocarditis. The median time from procedure to infective
endocarditis hospitalization was 352 days in the TAVR group
and 625 days in the SAVR group. The cumulative 5-year risk
of infective endocarditis was 5.8% and 5.1% in the TAVR
and SAVR population, respectively—hence, the long-term risk
of infective endocarditis was similar following TAVR and
SAVR (58).
In a large collaborative study, a total of 250 cases of infective
endocarditis occurred in 20,006 patients after TAVR (incidence,
1.1% per person-year; 95% CI, 1.1–1.4%; median age, 80 years;
64% men). Median time from TAVR to infective endocarditis
was 5.3 months [interquartile range (IQR), 1.5–13.4 months].
The characteristics associated with higher risk of progressing
to infective endocarditis after TAVR was younger age [78.9
years vs. 81.8 years; hazard ratio (HR), 0.97 per year], male sex
(62.0% vs. 49.7%; HR, 1.69), diabetes mellitus (41.7% vs. 30.0%;
HR, 1.52), and moderate to severe aortic regurgitation (22.4%
vs. 14.7%; HR, 2.05). Patients who developed endocarditis had
high rates of in-hospital mortality (36%) and 2-year mortality
(66.7%) (59).
The same prophylactic measurements to prevent infective
endocarditis have to be implemented following AVR with
a surgical or transcatheter aortic bioprosthesis. In case of
suspicion of prosthetic valve endocarditis in a TAVR patient,
the diagnosis with TEE may sometimes be challenging—
in such cases, use of intracardiac echocardiography (ICE)
and PET-CT could be considered (58, 60). In case of
prosthetic valve endocarditis following TAVR, the therapeutic
options are most of the time limited to antibiotic medical
treatment. Limited data from the Copenhagen group indicate
that such conservative approach is associated with a 22%
mortality rate. As reported by Olsen et al. (60), 17 out of
18 TAVR patients with infective endocarditis were treated
conservatively and one with surgery. Four patients (22%)
died from endocarditis or complications to treatment, two
of those (11%) during initial hospitalization for prosthetic
valve endocarditis (60).
CONCLUSIONS
With the expansion of TAVR to patients with longer
life expectancy, data on long-term THV durability are
essential. The first studies reporting on SVD up to 8
years after TAVR show low rates of THV degeneration.
Importantly, the release of standardized definitions on
bioprosthetic valve dysfunction represents a fundamental
step in allowing obtaining a better insight into its
real incidence.
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